Bill Alpert is a Senior Writer who covers finance and investment topics for various publications including MarketWatch, Private Equity News, Yahoo Finance, and Financial News. His work has also been featured in Barron's and The Organized Crime and Corruption Reporting Project. Bill's articles often focus on hedge funds, asset management, and market trends.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
New York, New York, United States (Local)
Bill Alpert primarily covers investment analysis, with a significant focus on financial news and legal policy regulation. Based on his coverage attributes, he is likely to be receptive to pitches that provide in-depth investment analysis or cite relevant data from reputable sources.
Given the high percentage of coverage attributed to legal policy regulation, it's evident that Bill may also be interested in topics related to SEC regulations, compliance issues within the finance industry, or legal developments impacting investments.
He doesn't have a specific geographic focus but focuses mainly on the United States. Therefore, tailored pitches providing insights into US-based financial markets and regulatory changes would likely resonate well with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Bill Alpert
Voyager Therapeutics has surely tried investors’ patience since it came public eight years ago. The biotech firm’s stock has fallen as low as $2.50 from a peak of $30, as its early programs to treat neurological diseases didn’t pan out. Analysts at Guggenheim Securities initiated coverage of the Lexington, Mass.-based biotech with a Buy rating earlier this week.
By: Bill Alpert
The lenders known as mortgage real estate investment trusts have a prominent spot on the injured list of players in commercial property.
Last year was one of the slowest in decades for bank mergers. While the deal environment remains harsh, Raymond James sees some potential targets.
Two rivals of the embattled lender said they had hired away private-bank teams responsible for billions of dollars in deposits.
By: Bill Alpert
Slow but steady progress was evident at a meeting of cancer researchers this week. A decade from now, these blood tests could be used to flag the more than 60% of deadly cancers that currently lack any way to screen for them.
By: Bill Alpert
Investors shelved their hopes for a pioneering cancer blood test after Illumina ‘s $8 billion acquisition of start-up Grail was scuttled by antitrust regulators last year. A decade from now, these blood tests could be used to flag the more than 60% of deadly cancers that currently lack any way to screen for them. At the annual meeting of the American Association for Cancer Research in San Diego, Exact Sciences reported on a 6,000-sample study of a multi-cancer test it plans to offer alongside single-cancer screening products such as its well-known Cologuard stool-based test for colon cancer.
How KKR’s profits grew fourfold in 10 years
By: Bill Alpert
Investors have sold nonvoting shares following news Shari Redstone has agreed to sell her voting stock at a premium.
A law banning China-owned TikTok grew more likely, with its hitching to an aid bill for Ukraine and Israel set for a Saturday vote. Washington watchers put high odds on the ban going to the Senate next week, and then the White House for signing. “It’s going to pass this weekend, unless something really weird happens,” says Paul Gallant, of TD Cowen’s Washington Research Group.
Senators have discussed additions to FAA legislation that would regulate stablecoins and allow state-licensed cannabis operations to use the federal banking system.
(833) 317-6278 
